toripalimab,paclitaxel
junshi biosciences,coherus
['toripalimab', 'tnbc', 'junshi']
at the ongoing 2023, junshi biosciences reported promising results from a phase iii trial comparing toripalimab to placebo in combination with nab-p in metastatic or recurrent tnbc patients. visit for a more detailed analysis: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry